CRMD - CorMedix GAAP EPS of -$0.19 beats by $0.02 revenue of $0.02M

• CorMedix press release ( NASDAQ: CRMD ): Q2 GAAP EPS of -$0.19 beats by $0.02 .
• Revenue of $0.02M (+100.0% Y/Y).
• Joe Todisco, CorMedix CEO, commented, “While I am disappointed that we will not receive FDA approval on our PDUFA date, I remain confident in our pathway forward to an FDA approval, once either our existing CMO and API supplier obtain compliance clearance, or we are able to obtain regulatory approval for manufacturing with Alcami. We have sufficient cash on hand to fund operations through at least the next four quarters, and the team is focused on obtaining FDA approval of the DefenCath NDA as quickly as possible. We look forward to providing additional updates as we aim to deliver on our commitment to these patients.”

For further details see: